Quick Links

JAKPOT T1D

JAKPOT T1D

For people age 12 – 35 years who have been diagnosed with type 1 diabetes in the past 3 months, this study tests two JAK inhibitors (abrocitinib and ritlecitinib) to see if either or both can preserve insulin production.

TrialNet researchers are testing two different JAK inhibitors – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).

JAK inhibitors are a new type of treatment researchers are studying in people who have autoimmune conditions. Researchers believe abrocitinib and ritlecitinib may be able to calm the immune system response that harms insulin-producing beta cells in the pancreas. Continuing to make even a small amount of insulin helps keep blood glucose levels in the normal range, lowering the risk of long-term complications.

To understand which treatment works best, participants will be randomly assigned to one of three groups: one will get abrocitinib, one will get ritlecitinib, and one will get a matching placebo (looks like a study drug but has no active ingredients).

JAKPOT is a two-year study. For the first year, you will take an oral tablet daily and visit a study site every three months for tests and monitoring. For the second year, you will no longer take treatment and will have follow-up clinic visits every six months.

Participants in the study will receive personalized coaching in diabetes management.
Study visits take place at our Clinical Research Center in Seattle, and at other TrialNet sites across the US.

https://www.trialnet.org/our-research/newly-diagnosed-t1d/jakpot-t1d

Participant Eligibility

You may be eligible to participate if you:
• are 12 – 35 years,
• are newly diagnosed with T1D (in past 3 months),
• have hemoglobin A1C below 10%,
• and are fully vaccinated for COVID-19 and influenza

Contact

the BRI Outreach Team
(800) 888-4187

Additional Study Details

Full Study Title
JAK Inhibitors in New Onset T1D

Study ID: SITE00000199
Start Date: 07/05/2023
End Date: 08/31/2026

Investigator(s)
Carmella Evans-Molina, MD, PhD
Sandra Lord, MD

Accepts Healthy Volunteers?
No

Study Site(s)

Benaroya Research Institute

1201 9th Ave
Seattle, Washington 98101



Interested?

Use the link below to send a message to the study coordinator, or call the number above to speak directly with a study representative.

I am interested in this research study.

SITE PARTNERS
uw-footer